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the study spreads and oils according to our specification, but was not involved in the design, 
implementation, analysis or interpretation of the data. 
 
Running head: Dietary fat, progenitor cells and microparticles 
 
Abbreviations: %TE, percentage of total energy; AIx, augmentation index; CRP, C reactive 
protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; DIVAS, Dietary 
Intervention and VAScular function; EPC, endothelial progenitor cells; EMP, endothelial 
microparticles; FMD, flow-mediated dilatation; MP, microparticles; PMP, platelet microparticles. 
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Abstract 1 
Background 2 
Endothelial progenitor cells (EPC) and microparticles (MP) are emerging novel markers of 3 
cardiovascular disease (CVD) risk, which could potentially be modified by dietary fat. We have 4 
previously shown that replacing dietary saturated fat (SFA) with monounsaturated (MUFA) or n-5 
6 polyunsaturated fat (PUFA) improved lipid biomarkers, blood pressure and markers of 6 
endothelial activation, but their effects on circulating EPCs and MPs are unclear. 7 
Objective 8 
The Dietary Intervention and VAScular function (DIVAS) study investigated the replacement of 9 
9.5-9.6% total energy (%TE) SFA with MUFA or n-6 PUFA for 16 weeks on EPC and MP 10 
numbers in UK adults with moderate CVD risk. 11 
Design 12 
In this randomized, controlled, single-blind, parallel group dietary intervention, men and women 13 
aged 21-60 y (n=190) with moderate CVD risk (≥50% above the population mean) consumed one 14 
of three 16-week isoenergetic diets. Target compositions for total fat, SFA, MUFA and n-6 15 
PUFA (%TE) were: SFA-rich diet (36:17:11:4, n=64), MUFA-rich diet (36:9:19:4, n=62) and n-6 16 
PUFA-rich diet (36:9:13:10, n=66). Circulating EPC, endothelial MP (EMP) and platelet MP 17 
(PMP) numbers were analysed by flow cytometry. Dietary intake, vascular function and other 18 
cardio-metabolic risk factors were determined at baseline.  19 
Results 20 
Relative to the SFA-rich diet, MUFA and n-6 PUFA-rich diets decreased EMP (-47.3%, -44.9%) 21 
and PMP numbers (-36.8%, -39.1%) (overall diet effects P<0.01). The MUFA-rich diet increased 22 
EPC numbers (+28.4%; P=0.023). Additional analyses using stepwise regression models 23 
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identified the augmentation index (measuring arterial stiffness determined by pulse wave 24 
analysis) as an independent predictor of baseline EPC and MP numbers.     25 
Conclusions 26 
Replacing 9.5-9.6%TE dietary SFA with MUFA increased EPC numbers and replacement with 27 
either MUFA or n-6 PUFA decreased MP numbers, suggesting beneficial effects on endothelial 28 
repair and maintenance. Further studies are warranted to determine the mechanisms underlying 29 
the favourable effects on EPC and MP numbers following SFA replacement.  30 
 31 
Keywords: Endothelial progenitor cells, Microparticles, Saturated fat, Monounsaturated fat, 32 
Polyunsaturated fat  33 
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Introduction 34 
Endothelial dysfunction occurs when the balance between endothelial injury and repair is 35 
disrupted (1). Microparticles (MP) are small (0.1-1µm) cell-derived vesicles released from the 36 
surface of many cell types, including endothelial cells and platelets, during apoptosis or 37 
activation, which may occur during endothelial injury. There is growing evidence for their use as 38 
diagnostic biomarkers for cardiovascular diseases (CVD) and their potential as pharmacological 39 
targets (2). Although present in healthy subjects, MP numbers are elevated in individuals with 40 
CVD and associated risk factors (2, 3), and addition of endothelial MP (EMP) numbers to the 41 
Framingham risk score model improves its prediction power of future CVD events (4). The 42 
impact of dietary and lifestyle factors on MP numbers is unclear. High fat meals acutely increase 43 
numbers of MP (5, 6), particularly when containing SFA and thermally-oxidised PUFA (7), 44 
supporting the well-accepted relationship between postprandial lipemia and endothelial activation 45 
(8). Very few studies have examined the chronic effects of dietary fat composition on MP 46 
numbers; we recently demonstrated decreased numbers of EMP, but not platelet microparticles 47 
(PMP), following fish oil supplementation (9).  48 
While MP are associated with endothelial injury, circulating bone marrow-derived 49 
endothelial progenitor cells (EPC) home to sites of endothelial injury where they induce 50 
neovascularization (10), potentially playing an important role in preserving the structural and 51 
functional integrity of the endothelium. Reduced EPC numbers and function are associated with 52 
CVD risk factors, including hypertension and hypercholesterolemia, and there is interest in the 53 
potential role of EPC as prognostic and/or diagnostic markers of CVD. However, clear data 54 
regarding the influence of dietary fat quality on the balance between endothelial injury and repair 55 
is limited. 56 
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Reduction of SFA intake to ≤10% of total energy (%TE) is a key public health strategy to 57 
reduce CVD risk (11). Replacing SFA with unsaturated fat, rather than carbohydrate, may afford 58 
greater CVD risk reduction (12, 13), yet it is not clear whether MUFA or n-6 PUFA have 59 
comparable effects on risk reduction or on emerging cellular markers of CVD risk (14). We 60 
recently demonstrated in the Dietary Intervention and VAScular function (DIVAS) study that 61 
substituting 9.5-9.6 %TE dietary SFA with either MUFA or n-6 PUFA did not significantly affect 62 
flow-mediated dilatation (FMD; primary outcome), but there were beneficial effects on lipid 63 
biomarkers, blood pressure and circulating E-selectin (15). Since the modification of dietary fat 64 
intake affects cellular markers of vascular function in the absence of alterations in FMD and 65 
previous studies suggest an impact of dietary fat composition on EPC numbers, this article 66 
presents additional outcome measures from the DIVAS study exploring the effect of substituting 67 
SFA with MUFA or n-6 PUFA on circulating EPC and MP numbers in subjects with moderate 68 
CVD risk. Multiple regression analyses also determined which dietary and CVD risk factors 69 
influence numbers of EPC and MP at baseline.   70 
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Methods 71 
Study participants and design 72 
The protocol for the DIVAS study has been described in full by Vafeiadou et al. (15). In 73 
summary, the study was a single-blind, randomized controlled parallel group study 74 
(NCT01478958) conducted according to the guidelines laid down in the Declaration of Helsinki. 75 
A favourable ethical opinion for conduct was given by the West Berkshire Local Research Ethics 76 
Committee (09/H0505/56) and the University of Reading Research Ethics committee (project 77 
number 09/40). Subjects provided written informed consent before participating. Non-smoking 78 
males and females aged 21-60 y with moderate CVD risk were recruited from Reading and the 79 
surrounding area in three cohorts between November 2009 and June 2012. A scoring tool 80 
described by Weech et al. identified individuals with a moderate risk of developing CVD (≥50% 81 
above the population mean) (16). Further inclusion criteria included normal blood biochemistry 82 
for liver and kidney function, not taking dietary supplements, not taking medication for 83 
hypertension, hypercholesterolemia, hyperlipidemia or inflammatory disorders, had not suffered 84 
from a myocardial infarction or stroke during the past 12 months or been diagnosed with 85 
diabetes, not pregnant or lactating, not consuming excessive amounts of alcohol (≤21 units for 86 
males and ≤14 units for females) and not participating in excessive amounts of aerobic exercise 87 
(≤3 x 20 min per week).  88 
 89 
Dietary intervention 90 
The food-exchange model for the dietary intervention has been described by Weech et al. (16). In 91 
brief, participants (n=202) were randomized (using minimization to match for age, gender, BMI 92 
and CVD risk score) to one of three 16 week intervention diets that aimed to replace 8%TE SFA 93 
with MUFA or n-6 PUFA. The target fatty acid compositions (as %TE) were as follows: SFA-94 
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rich diet (17% SFA, 11% MUFA and 4% n-6 PUFA); MUFA-rich diet (9% SFA, 19% MUFA 95 
and 4% n-6 PUFA); or n-6 PUFA-rich diet (9% SFA, 13% MUFA and 10% n-6 PUFA). All three 96 
isoenergetic diets provided 36%TE total fat, and n-3 PUFA, protein and carbohydrate were 97 
unchanged. The main sources of fats in the intervention diets were butter (SFA), refined olive oil 98 
and olive oil/rapeseed oil blended spread (MUFA) and safflower oil and spread (n-6 PUFA). 99 
Subjects were blinded to the diet allocation. Dietary intakes were determined from four day 100 
weighed diet diaries completed at baseline (week 0) and during the intervention (weeks 8 and 16), 101 
which were analyzed using Dietplan 6.6 (Foresfield, Horsham, UK). Following the intervention, 102 
target intakes were met or exceeded, and a greater replacement of SFA for MUFA (9.5%TE) and 103 
n-6 PUFA (9.6%TE) was achieved (16). For simplicity, the SFA-rich, MUFA-rich and n-6 104 
PUFA-rich diets will be referred to as the SFA, MUFA and n-6 PUFA diets going forward.    105 
 106 
Clinical and Biochemical analyses  107 
As described in full by Vafeiadou et al. (15), volunteers attended the Hugh Sinclair Unit of 108 
Human Nutrition (University of Reading, UK) at baseline (visit 1) and week 16 (visit 2) 109 
following an overnight fast. At each visit, non-invasive measurements of vascular function were 110 
performed: FMD (primary outcome), laser Doppler imaging with iontophoresis, pulse wave 111 
velocity, pulse wave analysis (determining the augmentation index (AIx)), and digital volume 112 
pulse (determining the stiffness and reflection indexes). 24 h ambulatory blood pressure and 113 
anthropometric measurements were also recorded. Fasting serum lipids, glucose and C-reactive 114 
protein (CRP) were analyzed using an ILAB600 clinical chemistry analyzer (Werfen UK Ltd, 115 
Warrington, UK). Insulin resistance was determined using HOMA-IR (17), and 10 y CVD risk 116 
was estimated using the validated QRISK®2-2013 CVD risk calculator (http://qrisk.org) (18). 117 
Plasma insulin and circulating markers of endothelial activation and inflammation (intercellular 118 
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adhesion molecule-1, vascular cell adhesion molecule-1, IL-6, TNFα, sE-selectin, sP-selectin, 119 
and von Willebrand Factor) were analyzed by commercial ELISA kits, plasma nitric oxide by 120 
chemiluminescence (15), and plasma phospholipid fatty acid composition by gas chromatography 121 
(16). Results for these outcome measures in response to the dietary intervention have been 122 
discussed previously (15, 16) and will not be presented again here. 123 
Enumeration of EPC, EMP and PMP 124 
EPC, EMP and PMP were analyzed by flow cytometry as previously described (9). CD34+KDR+ 125 
cells were defined as EPC and expressed as number of cells/mL of blood. EMP were defined as 126 
CD31+CD42b- particles and PMP as CD31+CD42b+ particles, both reported as counts/µL of 127 
blood.   128 
Statistical analysis 129 
The sample size was powered on the basis of a 2% (SD 2.3%) intergroup difference in %FMD, 130 
which was the primary outcome as reported in (15), with a 5% significance level and power of 131 
90%. At this level of power, 171 participants were required (n=57 per group), which increased to 132 
228 to include a 25% dropout rate (n=76 per group). This article reports further secondary 133 
outcomes of the DIVAS study (EPC and MP). For continuous variables, suitable checks of 134 
normality were implemented as appropriate. Differences between the diet groups at baseline were 135 
determined using one-way ANOVA and Chi-squared tests (gender). The General Linear Model 136 
was used to analyze the change from baseline (V2-V1) for EPC, EMP, and PMP when comparing 137 
the three dietary groups. The model included the baseline values of each corresponding variable 138 
of interest, age, gender, BMI and diet group as prognostic factors. Where the overall diet effect 139 
was significant, differences between diet groups were determined by post-hoc analyses using the 140 
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Tukey adjustment for multiple treatment comparisons to control for type 1 errors, and one sample 141 
t-tests determined whether the change from baseline was significantly different to zero for each 142 
diet. Statistical significance was assumed if P≤0.05 and statistical analyses were performed using 143 
SPSS version 21.0 (SPSS Inc.). In the tables and text, data are expressed as mean ± SE or % 144 
changes. LSMeans ± SE are presented in the figures.  145 
 146 
Stepwise regression analysis was performed as an additional analysis to determine which 147 
independent CVD risk factors influenced numbers of EPC, EMP or PMP using pre-intervention 148 
baseline (V1) data. Independent factors included the DIVAS outcome measures (vascular 149 
function, 24 h ambulatory blood pressure, biochemical markers of CVD risk and anthropometric 150 
measures), dietary factors (macronutrient intakes (as %TE) and plasma phospholipid fatty acid 151 
composition), CVD risk scores (DIVAS scoring tool and QRISK), age, gender, menstrual status, 152 
family history of early onset type 2 diabetes mellitus or myocardial infarction, and ethnicity (15, 153 
16). To avoid multicollinearity, only the most clinically-relevant independent factor was included 154 
where a pair of independent variables were highly correlated (two-tailed Spearman’s correlation 155 
coefficients) and a variance inflation factor of <5 was set. Only related independent variables, 156 
where P<0.15 following an initial linear regression between the dependent (EPC, EMP or PMP) 157 
and independent variable, were used in the corresponding stepwise regression model. Stepwise 158 
selection of variables used entry and removal parameters of F<0.05 and F>0.10, respectively, and 159 
missing values were excluded listwise. Unstandardized β coefficients ± SE are presented, where 160 
P<0.05 (determined by t-tests) were considered significant.   161 
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Results 162 
Of the 202 subjects randomized to the intervention (the flow of participation is presented in 163 
Supplemental Figure 1), seven subjects withdrew from the study before completion and EPC 164 
and MP data was not available for five subjects (n=190). There were no differences in the 165 
baseline characteristics of the subjects between the diet groups (Table 1). The combined mean (± 166 
SE) age was 44 ± 1 y and BMI was 26.6 ± 0.3 kg/m2.  167 
  168 
Effect of replacement of SFA with MUFA or n-6 PUFA on EPC numbers 169 
There were no significant differences in baseline EPC numbers between the three intervention 170 
groups (Supplemental Table 1). When expressed as changes from baseline (V2-V1), there was a 171 
significant overall effect of diet for EPC (P=0.023). Post-hoc analysis showed that when 172 
compared with the SFA group, EPC numbers significantly increased by 28.4% in the MUFA 173 
group after 16 weeks (P=0.017) (Supplemental Table 1 and Figure 1A). No differences were 174 
observed between the n-6 PUFA group and the MUFA or SFA groups. Furthermore, within-175 
group analysis showed that the MUFA diet significantly increased EPC numbers by 27.3% 176 
compared with baseline (P≤0.001), but the SFA (-1.1%; P=0.846) and n-6 PUFA (+9.1%; 177 
P=0.130) diets had little impact on EPC numbers.  178 
Effect of replacement of SFA with MUFA or n-6 PUFA on MP numbers 179 
At baseline, EMP and PMP numbers were similar in the three intervention groups (Supplemental 180 
Table 1). There were significant overall diet effects for changes in EMP and PMP numbers (both 181 
P ≤0.001). When SFA was replaced by MUFA, numbers of EMP decreased by 47.3% (P ≤0.001) 182 
and PMP by 36.8% (P= 0.002) after 16 weeks (Figures 1B and 1C). Likewise, an exchange of 183 
SFA for n-6 PUFA reduced numbers of EMP (-44.9%; P ≤0.001) and PMP (-39.1%; P ≤0.001). 184 
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There were no differences between the MUFA and n-6 PUFA groups for EMP or PMP. Within-185 
group differences from baseline further revealed significant reductions in EMP (-30.1%; P 186 
≤0.001) and PMP (-22.4%; P ≤0.001) following the n-6 PUFA diet. The MUFA diet also resulted 187 
in reductions in EMP (-32.5%; P ≤0.001) and PMP (-20.1%; P= 0.002) relative to baseline. 188 
Finally, the SFA diet increased numbers of EMP (+14.7%; P= 0.010) and tended to increase PMP 189 
(+16.7%; P= 0.073) after 16 weeks.     190 
 191 
Influence of CVD risk factors on numbers of circulating EPCs and MPs at baseline 192 
To determine which CVD risk factors influence numbers of EPCs and MPs, stepwise regression 193 
analysis was performed using the pre-intervention data collected at baseline (V1). This defined 194 
the total variance explained by the independent predictors identified in the model (r2 adjusted) 195 
and the impact that 1 unit change of the independent variable had on EPC or MP numbers 196 
(unstandardized β). Three independent factors were identified that predicted higher EPC 197 
numbers: reduced arterial stiffness as measured by AIx (β= -18.0 (SE(β)= 4.6), P <0.001), a 198 
higher night-time diastolic blood pressure (DBP) (β= 18.7 (SE(β)= 7.7), P= 0.016) and a lower 199 
dietary total sugar intake (β= -19.5 (SE(β)= 9.4), P= 0.039) (Supplemental Table 2). However, 200 
this model only explained 11.0% of the variance for EPC. Four predictors were identified that 201 
predicted higher EMP, explaining 14.5% of the variance. These were increased arterial stiffness 202 
(AIx: β= 0.72 (SE(β)= 0.21), P= 0.001), higher plasma P-selectin (β= 0.55 (SE(β)= 0.20), P= 203 
0.007) and TNFα concentrations (β= 9.03 (SE(β)= 3.99), P= 0.025), and lower CRP (β= -1.95 204 
(SE(β)= 0.73), P= 0.008). For the final model (explaining only 5.2% of the variance), high PMP 205 
numbers were also predicted by higher AIx (β= 2.58 (SE(β)= 1.12), P= 0.023) as well as lower 206 
microvascular reactivity (measured by laser Doppler imaging with iontophoresis of 1% 207 
acetylcholine) (β= -0.04 (SE(β)= 0.02), P= 0.029).  208 
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Discussion 209 
This study demonstrates, for the first time, that substituting 9.5-9.6%TE of dietary SFA with 210 
MUFA in free-living adults for 16 weeks significantly increases numbers of EPC and substitution 211 
with either MUFA or n-6 PUFA decreases numbers of both EMP and PMP, suggesting 212 
favourable effects on the repair and maintenance of the endothelium when SFA is substituted for 213 
unsaturated fatty acids. Replacement of dietary SFA by MUFA or PUFA is widely believed to 214 
reduce the risk of CVD, more so than if SFA are replaced by carbohydrate (13). A recent review 215 
concluded that ‘the benefits of polyunsaturated fat appear strongest’, but this comment relates to 216 
both n-6 and n-3 PUFA (19), and the available data on MUFA interventions with hard endpoints 217 
is limited. One such study (PREDIMED) reported that greater intakes of MUFA-rich olive oil, 218 
particularly the extra-virgin varieties, significantly reduced CVD risk and mortality in individuals 219 
at high cardiovascular risk (20). Although the individual effects of MUFA and n-6 PUFA on 220 
CVD risk remain unclear, there is often active discouragement of high intakes of n-6 PUFA 221 
(>10%TE) and a preference for MUFA as a strategy to prevent CVD (21).  222 
To our knowledge, no other chronic study has determined the impact of replacing SFA 223 
with n-6 PUFA. In the current study, there was a reduction in MP when SFA were replaced with 224 
n-6 PUFA. In contrast, a n-6 PUFA-rich meal (sunflower oil) increased postprandial circulating 225 
CD144-EMP in healthy subjects relative to a SFA-rich meal (cream), although clearly this was an 226 
acute setting and the sample size was small (n=22) (22). While there are two published studies 227 
supporting a reduction in numbers of MPs and increase in numbers of EPCs following a MUFA-228 
rich diet (23, 24), the studies were small and technical issues regarding the EPC and MP analysis 229 
cast some doubt on the data. The first study, which replaced a SFA-rich diet (38%TE total fat, 230 
22%TE SFA (butter) and 12%TE MUFA) with a MUFA-rich Mediterranean diet (38%TE total 231 
fat, <10%TE SFA and 24%TE MUFA (virgin olive oil)) in 20 elderly subjects for 4 weeks, 232 
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reported higher circulating EPC numbers and lower numbers of total MP (23). In the second 233 
study, consumption of a 12-week hypocaloric Mediterranean diet rich in MUFA (30%TE total 234 
fat, 5%TE SFA, 20%TE MUFA (virgin olive oil), and 5%TE PUFA) increased EPC numbers 235 
relative to baseline in 45 patients with metabolic syndrome (24). However, neither study 236 
employed standardized beads to allow absolute counting of samples (23, 24). In addition, Marin 237 
et al. (23) failed to describe their gating strategies and presented their EPC data as a percentage, 238 
but did not specify what this referred to, making it difficult to assess the validity of the data. The 239 
DIVAS study used refined olive oil, being the first to show that increased MUFA intake in the 240 
absence of phenolic compounds had beneficial effects on EPC and MP numbers. Since the 241 
increase observed in EPC numbers was only significant when SFA was replaced by MUFA, 242 
further investigation to understand the different effects of MUFA and n-6 PUFA is warranted.    243 
Findings from the baseline regression analyses suggest that AIx, a measure of arterial 244 
stiffness, may influence EPC and MP numbers, since an increase in AIx was associated with 245 
lower EPC and higher MP numbers. Structural alterations to the arterial walls, such as changes to 246 
the elastin to collagen ratio that occur naturally with aging, reduce their elasticity. Increased 247 
stiffness puts stress on the arterial walls and increases the risk of plaque rupture, which both 248 
enhance the likelihood of CVD events (25). At present, very limited data suggests a link may 249 
exist between arterial stiffness and numbers of EPC or MP (26, 27). For example, greater arterial 250 
stiffness (as assessed by aortic pulse wave velocity) was reported in subjects with the lowest EPC 251 
and highest MP counts, even after controlling for the Framingham risk score (26). Since 252 
vasoactive drugs significantly improved AIx in healthy men (28), one could hypothesize that 253 
vasodilator drugs may indirectly improve EPC and MP numbers as a means of repairing and 254 
maintaining the endothelium, in part via their beneficial effect on AIx, thus lowering CVD risk. 255 
This potential relationship warrants further investigation. Higher circulating numbers of EMP 256 
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were also predicted by greater concentrations of P-selectin and TNFα (markers of endothelial 257 
activation and inflammation, respectively). Tan et al. reported a ‘modest’ correlation between 258 
PMP and P-selectin (r= 0.345, P <0.001), both of which were the only predictors of peripheral 259 
artery disease severity in multivariate analysis (29). Furthermore, greater concentrations of P-260 
selectin-positive PMP were reported in older adults with CVD compared with young healthy 261 
subjects (30), which may facilitate the recruitment of leukocytes and platelets to the endothelium 262 
during endothelial dysfunction.   263 
The primary outcome of the DIVAS study, FMD, measured macrovascular reactivity, but 264 
this was not identified as a predictor of EPC or MP numbers. In contrast, a reduction in 265 
microvascular reactivity, as measured by laser Doppler imaging in response to acetylcholine, did 266 
appear to have a detrimental impact on PMP numbers, suggesting a potential mechanism relating 267 
the regulation of the microcirculation to the release of PMP. However, blood pressure, which is 268 
closely related to microvascular reactivity (31), did not appear to impact numbers of PMP.     269 
Excessive body weight has previously been associated with decreased numbers of EPCs 270 
and increased numbers of MPs (32), and weight reduction is reported to restore EPC numbers 271 
(33). However, in the current analysis, which is significantly larger than previous studies, there 272 
was no influence of BMI or waist-to-hip ratio at baseline on numbers of EPCs or MPs. 273 
Furthermore, the beneficial effects of SFA substitution with unsaturated fats on EPC and MP 274 
numbers were not related to changes in weight as there were no differences in BMI or central 275 
adiposity between the diet groups after 16 weeks (16). In addition, EPC and MP numbers were 276 
not dependent on gender; to our knowledge, this is the first time the influence of gender on 277 
numbers of MPs in a large cohort has been investigated. Numbers of EPCs and MPs were also 278 
not dependent on age, ethnicity, baseline fasting blood lipids, glucose or insulin. Chronic 279 
exposure to CVD risk factors is thought to reduce the mobilization of EPC, thus reducing their 280 
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numbers in the circulation (34). The subjects recruited into this study were defined as having 281 
moderately elevated risk of CVD (≥50% above the population average). Therefore, it is likely 282 
that the lack of association with CVD risk factors at baseline was due to the small proportion of 283 
subjects identified as being ‘at risk’ as a result of any one parameter, which could be considered a 284 
limitation of the analyses. Further investigation in single ‘at risk’ populations, e.g. hypertensives 285 
or hypercholesterolemics, is required. The main purpose of the current investigation, however, 286 
was to determine the effects of the dietary intervention on numbers of EPC and MP and a key 287 
strength was that compared with other studies (23, 24), it was conducted using a much larger 288 
sample size (n=190 vs n=20-45) and as such is the first chronic dietary intervention investigating 289 
the effects of exchange of SFA with n-6 PUFA on the newly emerging CVD risk markers, EPC 290 
and MP. Finally, multiple treatment comparisons were corrected for using the Tukey adjustment, 291 
consistent with the approach taken for the primary outcome analysis of the DIVAS data. It could 292 
be suggested that multiple endpoint analysis requires more powerful techniques to control for 293 
type 1 errors, such as the false discovery rate, although the need to maintain consistency in our 294 
statistical approach with previously published data was considered important in this case (35).    295 
In conclusion, a 16-week replacement of 9.5%TE dietary SFA with MUFA increased 296 
numbers of EPC and decreased numbers of MP in a population at moderate risk of CVD. 297 
Replacement of 9.6%TE dietary SFA with n-6 PUFA did not significantly affect numbers of 298 
EPC, but decreased numbers of both EMP and PMP. Further studies investigating SFA 299 
replacement are warranted to determine the mechanisms underlying the favourable effects on 300 
EPC and MP numbers, and basis for the differential effects of MUFA and n-6 PUFA.     301 
 302 
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Table 1. Baseline characteristics of study subjects1 
 
 
SFA group MUFA group n-6 PUFA group 
 (n=64) (n=61) (n=65) 
Age, y 45 ± 1 43 ± 1 45 ± 1 
Sex, M/F 28 / 36 25 / 36 29 / 36 
BMI, kg/m2 26.5 ± 0.5 26.3 ± 0.5 27.0 ± 0.5 
Waist:hip ratio 0.87 ± 0.01 0.85 ± 0.01 0.88 ± 0.01 
24h SBP, mm Hg 120 ± 2  120 ± 1 124 ± 2 
24h DBP, mm Hg 75 ± 1 74 ± 1 76 ± 1 
Fasting serum biomarkers    
   Total cholesterol, mmol/L 5.4 ± 0.1 5.5 ± 0.1 5.6 ± 0.2 
   LDL cholesterol, mmol/L 3.7 ± 0.1 3.7 ± 0.1 3.8 ± 0.1 
   Triacylglycerol, mmol/L 1.3 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 
   Glucose, mmol/L 5.1 ± 0.1 5.0 ± 0.1 5.1 ± 0.1 
CVD risk score1 3.3 ± 0.2 3.0 ± 0.2 3.4 ± 0.2 
Data are mean ± SEM. 1 No significant differences between the groups were identified 
for any of the baseline characteristics (one-way ANOVA except Chi-square for sex; 
P>0.05). 1 Determined using the DIVAS study screening tool (16). CVD: cardiovascular 
disease; DBP: diastolic blood pressure; SBP: systolic blood pressure.  
  
 25 
Figure 1. Effect of replacement of dietary SFA with MUFA or n-6 PUFA on 
numbers of EPC (A), EMP (B) and PMP (C) expressed as change from baseline. 
Data are presented as LSMeans ± SE for n=59-65 subjects per group. There was a 
significant effect of diet after 16 weeks for EPC, EMP and PMP (overall diet effects: P 
≤0.05; general linear model), in which post-hoc analyses (using Tukey correction to 
adjust for multiple treatments) identified significant differences between the SFA diet and 
both MUFA and n-6 PUFA diets (*P <0.05; **P <0.01; ***P ≤0.001). Abbreviations: ∆: 
change from baseline, EPC: endothelial progenitor cells, EMP: endothelial 
microparticles, PMP: platelet microparticles. 
